400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2020-09-25
FDA-2019-D-3805
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
This guidance provides information regarding how the basic safety and essential performance standards are incorporated into the Pilot Accreditation Scheme for Conformity Assessment Program (hereafter referred to as the ASCA Pilot). The ASCA Pilot is described in FDA's guidance The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program.
For the edition of the FDA-recognized consensus standard(s) included in the ASCA Pilot, see the FDA Recognized Consensus Standards Database. For more information regarding use of consensus standards in regulatory submissions, please refer to FDA's guidance Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devicesand Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2019-D-3805.
摩熵医械2025-11-28
摩熵医械2025-11-17
赛柏蓝2025-11-14
摩熵医械2025-11-12
赛柏蓝2025-11-12
CHC医疗传媒2025-10-30
赛柏蓝2025-10-29
赛柏蓝2025-10-28
赛柏蓝2025-10-24
赛柏蓝2025-10-24
2025-12-01
2025-11-27
2025-11-26
2025-11-24
2025-11-24
2025-11-21
2025-11-18
2025-11-18
2025-11-17
2025-11-13
2025-11-13
2025-11-13
2025-11-11
2025-11-11
2025-11-11
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2025-11-17
2025-09-17
2025-09-17
2025-09-17
2025-07-21
2025-02-05
2025-01-31
2025-01-31
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07